Distinctive low epidermal nerve fiber density in schwannomatosis patients provides a major parameter for diagnosis and differential diagnosis

Schwannomatosis and neurofibromatosis type 2 (NF2) are two distinct neuro‐genetic tumor predisposition disorders, which, however, share some clinical and genetic features. While germline mutations in the NF2 gene are only found in NF2, a majority of schwannomatosis patients have germline mutations in the SMARCB1 or LZTR1 genes. The overlapping clinical phenotypes pose a serious challenge in differential diagnosis and in risk stratification of these two entities which is further complicated by frequent mosaicism in both disorders. Chronic neuropathic pain which is a typical consequence of small fiber neuropathy, is characteristic for schwannomatosis. By contrast, NF2 patients do not have chronic pain but may have moderate to severe sensory deficits and paresis which are not characteristic for schwannomatosis. In the present study, we determined intraepidermal nerve fiber density (IEND) in skin biopsies of 34 clinically ascertained schwannomatosis and 25 NF2 patients. In the NF2 group, 11/25 (44%) presented with IEND below the age‐ and gender‐matched bottom 5% normative reference IEND. In contrast, nearly all (33/34 = 97%) schwannomatosis patients showed IEND below or on the bottom 5% normative reference. The reduction of IEND in schwannomatosis patients was age‐independent. Paired t‐test revealed no difference between the NF2‐IEND and the corresponding bottom 5% normative reference (P = 0.98). By contrast, IEND in the schwannomatosis patients were highly significantly lower than the corresponding 5% normative reference IEND (P < 0.0001). In addition, the difference between the IEND of our patients and the 5% lowest normative reference IEND was highly significantly larger in schwannomatosis patients than in NF2 patients (P < 0.0001). IEND of our patients did not correlate with neither the presence nor types of germline mutations in neither the NF2 nor the LZTR1 gene. In conclusion, schwannomatosis patients have marked low IEND which provides a major parameter for diagnosis and differential diagnosis.

[1]  S. Heiland,et al.  Dorsal root ganglia volume differentiates schwannomatosis and neurofibromatosis 2 , 2018, Annals of neurology.

[2]  K. Gripp,et al.  Constitutional LZTR1 mutation presenting with a unilateral vestibular schwannoma in a teenager , 2017, Clinical genetics.

[3]  D. Evans,et al.  Revisiting neurofibromatosis type 2 diagnostic criteria to exclude LZTR1-related schwannomatosis , 2017, Neurology.

[4]  D. Cooper,et al.  The molecular pathogenesis of schwannomatosis, a paradigm for the co-involvement of multiple tumour suppressor genes in tumorigenesis , 2016, Human Genetics.

[5]  David T. W. Jones,et al.  Multifocal nerve lesions and LZTR1 germline mutations in segmental schwannomatosis , 2016, Annals of neurology.

[6]  Whole exome sequencing reveals that the majority of schwannomatosis cases remain unexplained after excluding SMARCB1 and LZTR1 germline variants , 2014, Acta Neuropathologica.

[7]  A. Stemmer-Rachamimov,et al.  Update from the 2011 International Schwannomatosis Workshop: From genetics to diagnostic criteria , 2013, American journal of medical genetics. Part A.

[8]  A. Stemmer-Rachamimov,et al.  Clinical features of schwannomatosis: a retrospective analysis of 87 patients. , 2012, The oncologist.

[9]  C. Schmitz,et al.  Intraepidermal nerve fiber density at the distal leg: a worldwide normative reference study , 2010, Journal of the peripheral nervous system : JPNS.

[10]  J. Valls-Solé,et al.  European Federation of Neurological Societies/Peripheral Nerve Society Guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy. Report of a joint task force of the European Fe‐deration of Neurological Societies and the Peripheral Nerve Society , 2010, European journal of neurology.

[11]  M. Nolano,et al.  European Federation of Neurological Societies/Peripheral Nerve Society Guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society , 2010, Journal of the peripheral nervous system : JPNS.

[12]  D. Evans,et al.  Mosaicism in neurofibromatosis type 2: an update of risk based on uni/bilaterality of vestibular schwannoma at presentation and sensitive mutation analysis including multiple ligation-dependent probe amplification , 2007, Journal of Medical Genetics.

[13]  E. A. Chiocca,et al.  Diagnostic criteria for schwannomatosis , 2005, Neurology.

[14]  S. Purcell,et al.  Somatic mosaicism in neurofibromatosis 2: prevalence and risk of disease transmission to offspring , 2003, Journal of medical genetics.

[15]  L. Kluwe,et al.  Molecular study of frequency of mosaicism in neurofibromatosis 2 patients with bilateral vestibular schwannomas , 2003, Journal of medical genetics.

[16]  B. Korf,et al.  The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. , 1997, Journal of the American Medical Association (JAMA).